002166，控制权或生变！停牌！

Core Viewpoint - The actual controller of Rhein Biotech, Qin Benjun, is planning a change in the company's control, leading to a stock suspension and a potential acquisition of at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. [1][2][5] Group 1: Control Change - Qin Benjun is preparing to transfer part of his shares and relinquish voting rights, indicating a potential change in control of Rhein Biotech [2][5] - A "Control Change Intent Agreement" has been signed by relevant parties, but specific transaction details are still under negotiation [5] - The transaction may result in a change of the controlling shareholder and actual controller of the company [5] Group 2: Acquisition Details - Rhein Biotech plans to acquire at least 80% of Beijing Jinkangpu, which will become a subsidiary and included in the consolidated financial statements [5][9] - The acquisition aims to enhance Rhein Biotech's capabilities in food and health product development, leveraging synergies between the two companies [9] Group 3: Company Background - Rhein Biotech specializes in the research, production, and sales of natural health products and is a leading player in the global plant extraction industry [12] - As of the end of the third quarter, Qin Benjun holds 271.39 million shares, representing 36.59% of the company [10][11] - The company's stock price was reported at 8.7 yuan per share, with a total market value of 64.52 billion yuan as of December 9 [13]